【摘要】 目的 评价棕榈酸帕利哌酮注射剂（PP-LAI）和利培酮长效注射剂（RLAI）治疗精神分裂症的有效性和安全性。方法 检索中国期刊全文数据库、中文期刊全文数据库、万方数据知识服务平台、PubMed和TheCochranelibrary等中英文数据库中关于PP-LAI和RLAI的临床随机对照试验，通过The Cochrane评分工具评估文献质量，再利用RevMan 5.4软件对数据进行Meta分析，从而比较两种药物治疗精神分裂症的有效性与安全性差异。结果 最终纳入10个随机对照试验，其中有效性分析集10个，包括2 629例患者；安全性分析集9个，包括2 984例患者。Meta分析结果显示，PP-LAI和RLAI治疗精神分裂症的有效率、治疗前后PANSS评分差值、治疗前后PSP评分差值、总不良反应发生率、心血管不良反应发生率、睡眠障碍发生率和催乳素相关不良反应发生率比较差异无统计学意义（P>0.05），而PP-LAI导致的锥体外系不良反应（EPS）和血糖相关不良反应发生率显著低于RLAI(P<0.05)。结论 PP-LAI和RLAI是临床常用的两种抗精神病药长效制剂，其治疗精神分裂症的疗效和安全性情况大体相当，但PP-LAI导致EPS和血糖相关不良反应的概率更低。临床应结合患者症状、病史和经济水平等因素，个体化地选择用药方案。更多还原

【Abstract】 Objective To evaluate the efficacy and safety of Paliperidone Palmitate Long-Acting Injection(PP-LAI) and Risperidone Long-acting Injection(RLAI) for schizophrenia. Methods Databases including CNKI, VIP, PubMed, and The Cochrane Library were searched to collect Randomized Controlled Trials(RCTs) on PP-LAI and RLAI. The Cochrane Collaboration’s tool was used to access the risk of bias, and RevMan 5.4 was used for meta-analysis, to compare the differences between the two drugs. Results 10 RCTs were eventually included. There are 10 efficacy analysis sets involving 2 629 patients and 9 safety analysis sets involving 2 984 patients. The results of the meta-analysis showed that there are no significant differences between PP-LAI and RLAI in effective rate, change from baseline to endpoint in PANSS and PSP score, the incidence of all adverse events(AEs), cardiac-related AEs, sleep disorders and prolactin-related AEs(P>0.05). However, the incidence of Extra Pyramidal Symptoms(EPS) and glucose-related AEs caused by PP-LAI was significantly lower than that caused by RLAI(P<0.05).Conclusion PP-LAI and RLAI are two long-acting antipsychotic agents commonly used in clinics. Their efficacy and safety in the treatment of schizophrenia are roughly equal, but the incidence of EPS and glucose-related AEs caused by PP-LAI is lower. Clinical medication should be selected individually based on patients’ symptoms, medical history and economic level.更多还原